Dr Jackson Thomas Pruett, PT, DPT | |
5860 Yadkin Rd, Fayetteville, NC 28303-2668 | |
(910) 491-5164 | |
Not Available |
Full Name | Dr Jackson Thomas Pruett |
---|---|
Gender | Male |
Speciality | Physical Therapy |
Experience | 5 Years |
Location | 5860 Yadkin Rd, Fayetteville, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013532498 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | P19589 (North Carolina) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Benchmark Physical Therapy Of North Carolina Llc | 1052609278 | 153 |
News Archive
The American Society of Nephrology strongly recommends that all adults undergo routine screening for chronic kidney disease (CKD), the 8th leading cause of death in the U.S. This contradicts screening guidelines recently released by the American College of Physicians (ACP).
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics' three currently available diagnostic tests.
IntriCon Corporation a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its third quarter ended September 30, 2010.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.
› Verified 8 days ago
Provider Name | Benchmark Physical Therapy Of North Carolina Llc |
---|---|
Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
Provider Identifiers | NPI Number: 1356894604 PECOS PAC ID: 1052609278 Enrollment ID: O20161004000926 |
News Archive
The American Society of Nephrology strongly recommends that all adults undergo routine screening for chronic kidney disease (CKD), the 8th leading cause of death in the U.S. This contradicts screening guidelines recently released by the American College of Physicians (ACP).
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics' three currently available diagnostic tests.
IntriCon Corporation a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its third quarter ended September 30, 2010.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Jackson Thomas Pruett, PT, DPT 953 Butler Dr, Erwin, NC 28339-8519 Ph: (919) 451-0212 | Dr Jackson Thomas Pruett, PT, DPT 5860 Yadkin Rd, Fayetteville, NC 28303-2668 Ph: (910) 491-5164 |
News Archive
The American Society of Nephrology strongly recommends that all adults undergo routine screening for chronic kidney disease (CKD), the 8th leading cause of death in the U.S. This contradicts screening guidelines recently released by the American College of Physicians (ACP).
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics' three currently available diagnostic tests.
IntriCon Corporation a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its third quarter ended September 30, 2010.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.
› Verified 8 days ago
Miss Roxanne King, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1700 Pamalee Drive, Fayetteville, NC 28303 Phone: 910-488-2295 | |
Kristi Wilkins, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1289 Oliver St, Fayetteville, NC 28304 Phone: 910-483-8331 Fax: 910-483-8335 | |
Dale Anthony Gallo Jr., DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4140 Ferncreek Dr Ste 802, Fayetteville, NC 28314 Phone: 910-484-2171 Fax: 910-484-4568 | |
Michael Andrew Slack, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1712 Owen Dr, Fayetteville, NC 28304 Phone: 910-483-9300 Fax: 910-483-9302 | |
Matthew Gregory Prindle, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 3401 Village Dr Ste 101, Fayetteville, NC 28304 Phone: 910-483-9300 Fax: 910-483-9302 | |
Casandra Heather Canterbury, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 501 Executive Pl, Fayetteville, NC 28305 Phone: 910-423-5550 Fax: 910-423-5552 | |
Tobi Alyssa Fuller, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1289 Oliver St, Fayetteville, NC 28304 Phone: 910-483-8331 Fax: 910-483-8335 |